[8]). In models in which an anti-tumor effect for VEGFR1 blockade was detected, they were attributed to direct effects on cancer cells or by modulation of angiogenesis [20], [24], but there was no data reported on hematogenous metastasis formation. This may be related to cell migration and MMP-9 activity in response to VEGFR1 activation in resident pulmonary macrophages and/or endothelial cells [19]. The gene discussed is MMP9; the disease is cancer.